Hound Partners, LLC Theravance Biopharma, Inc. Transaction History

Hound Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$6.77 - $14.41 $337,349 - $718,050	-49,830 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$14.52 - $22.46 $723,531 - $1.12 Million	49,830 New	49,830 $724,000
Q4 2020 Feb 16, 2021	SELL	$14.89 - $20.16 $851,708 - $1.15 Million	-57,200 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$14.79 - $22.49 $845,988 - $1.29 Million	57,200 New	57,200 $846,000
Q2 2018 Aug 14, 2018	SELL	$22.06 - $25.52 $928,328 - $1.07 Million	-42,082 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$23.37 - $29.71 $983,456 - $1.25 Million	42,082 New	42,082 $1.02 Million

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Hound Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Hound Partners, LLC with notifications on news.